Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — , /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company. We enter 2025 with a diversified portfolio of proprietary commercial products generating substantial profitability and an advancing development pipeline that represents a significant value creation opportunity in one of the most exciting potential new therapeutic categories in neuroscience," said Richard Pops, Chief Executive Officer of Alkermes. "Looking ahead, we are well positioned to deliver on our financial goals and advance the development programs for our portfolio of orexin 2 receptor agonists. This year, we have clear objectives for our pipeline as we complete the phase 2 studies for ALKS 2680 in narcolepsy, with data expected in the second half of the year, and prepare to initiate the ALKS 2680 phase 2 study in idiopathic hypersomnia and advance ALKS 4510 and ALKS 7290 into planned phase 1 studies in disease areas beyond central disorders of hypersomnolence. Each of these initiatives is an important element of our strategy to unlock what we believe is a multi-billion-dollar market opportunity for this category." "2024 was Alkermes' strongest year of financial and operational performance to date. Financially, we generated more than $1 billion in revenue from our proprietary commercial product portfolio, delivered EBITDA from continuing operations of approximately $452 million, repurchased $200 million of the company's ordinary shares, retired approximately $290 million of debt and ended the year debt-free with approximately $825 million of cash and investments on the balance sheet. Operationally, we completed the sale of our manufacturing business in Ireland and made significant progress advancing our neuroscience development pipeline," said Blair Jackson, Chief Operating Officer of Alkermes. "We will continue to manage the business with a sharp focus on efficiency and profitability as we invest in the programs that we believe will drive the company's next phase of growth." Key Financial Highlights Revenues (In millions) Three Months EndedDecember 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Total Revenues $ 430.0 $ 377.5 $ 1,557.6 $ 1,663.4* Total Proprietary Net Sales $ 307.7 $ 242.0 $ 1,083.5 $ 920.0 VIVITROL® $ 134.1 $ 102.4 $ 457.3 $ 400.4 ARISTADA®i $ 96.6 $ 83.4 $ 346.2 $ 327.7 LYBALVI® $ 77.0 $ 56.2 $ 280.0 $ 191.9 Profitability (In millions) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023* GAAP Net Income From Continuing Operations $ 145.7 $ 160.6 $ 372.1 $ 519.2 GAAP Net Income (Loss) From Discontinued Operations $ 0.8 $ (47.8) $ (5.1) $ (163.4) GAAP Net Income $ 146.5 $ 112.8 $ 367.1 $ 355.8 Non-GAAP Net Income From Continuing Operations $ 173.4 $ 81.8 $ 494.4 $ 396.5 Non-GAAP Net Income (Loss) From Discontinued Operations $ 0.8 $ (44.4) $ (5.1) $ (152.9) Non-GAAP Net Income $ 174.2 $ 37.4 $ 489.3 $ 243.7 EBITDA From Continuing Operations $ 170.0 $ 72.8 $ 452.4 $ 486.3 EBITDA From Discontinued Operations $ 1.1 $ (40.5) $ (5.8) $ (162.5) EBITDA $ 171.1 $ 32.3 $ 446.6 $ 323.8 *As a result of the successful resolution of the arbitration with Janssen Pharmaceutica N.V., the twelve months ended December 31, 2023 included approximately $195.4 million of back royalties (and related interest) related to U.S. net sales of long-acting INVEGA® products that would ordinarily have been recognized in prior periods. Revenue Highlights LYBALVI Revenues for the fourth quarter were $77.0 million. Fourth quarter revenues and total prescriptions grew 37% and 30%, respectively, compared to the fourth quarter of 2023. During the quarter, the company recorded LYBALVI® revenue of approximately $4 million related to year-end inventory fluctuations. ARISTADAi Revenues for the fourth quarter were $96.6 million. Fourth quarter revenues grew 16% compared to the fourth quarter of 2023. During the quarter, the company recorded ARISTADA® revenue of approximately $9 million related to year-end inventory fluctuations and gross-to-net favorability, primarily driven by Medicaid utilization adjustments. VIVITROL Revenues for the fourth quarter were $134.1 million. Fourth quarter revenues grew 31% compared to the fourth quarter of 2023. During the quarter, the company recorded VIVITROL® revenue of approximately $23 million related to year-end inventory fluctuations and gross-to-net favorability, primarily driven by Medicaid utilization adjustments. Manufacturing & Royalty Revenues Royalty revenues from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the fourth quarter were $36.5 million. VUMERITY® manufacturing and royalty revenues for the fourth quarter were $35.0 million. FAMPYRA® manufacturing and royalty revenues for the fourth quarter were $22.9 million. The company does not expect to record any FAMPYRA revenue going forward. RISPERDAL CONSTA® manufacturing revenues for the fourth quarter were $14.7 million. Key Operating Expenses Please see Note 1 below for details regarding discontinued operations. (In millions) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 R&D Expense – Continuing Operations $ 58.2 $ 73.9 $ 245.3 $ 270.8 R&D Expense – Discontinued Operations $ (1.1) $ 21.5 $ 5.8 $ 116.2 SG&A Expense – Continuing Operations $ 147.0 $ 169.8 $ 645.2 $ 689.8 SG&A Expense – Discontinued Operations $ - $ 19.4 $ - $ 48.6 Balance Sheet At Dec. 31, 2024, the company recorded cash, cash equivalents and total investments of $824.8 million, compared to $813.4 million at Dec. 31, 2023. In December 2024, the company prepaid and retired in full all of its outstanding long-term debt in the amount of approximately $290 million. Financial Expectations for 2025 All line items are according to GAAP, except as otherwise noted. In millions 2025 Expectations Total Revenues $1,340 – $1,430 VIVITROL Net Sales $440 – $460 ARISTADAi Net Sales $335 – $355 LYBALVI Net Sales $320 – $340 Cost of Goods Sold $185 – $205 R&D Expenses $305 – $335 SG&A Expenses $655 – $685 GAAP Net Income a $175 – $205 EBITDA $215 – $245 Adjusted EBITDA $310 – $340 Effective Tax Rate ~17% a Expected 2025 weighted average basic share count of approximately 165.5 million shares outstanding and a weighted average diluted share count of approximately 169.5 million shares outstanding. Notes and Explanations 1. The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, Discontinued Operations. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three and twelve months ended Dec. 31, 2023. Conference CallAlkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. EST (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com. Non-GAAP Financial MeasuresThis press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income, EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. Non-GAAP net income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items. EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense in addition to the components of EBITDA from earnings. The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income, EBITDA and Adjusted EBITDA should not be considered measures of the company's liquidity. A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. Note Regarding Forward-Looking StatementsCertain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including expected drivers of growth, value creation and profitability; and the company's expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, ALKS 2680 and the company's other orexin portfolio candidates. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations, including those related to profitability; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company's products or products using the company's proprietary technologies; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release. VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA TRINZA®, RISPERDAL CONSTA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; FAMPYRATM is a trademark of Merz Pharmaceuticals, LLC; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license. i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise. Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Statements of Operations - GAAP Three Months Ended Three Months Ended (In thousands, except per share data) December 31, 2024 December 31, 2023 Revenues: Product sales, net $ 307,726 $ 241,972 Manufacturing and royalty revenues 122,260 135,500 Research and development revenue — 3 Total Revenues 429,986 377,475 Expenses: Cost of goods manufactured and sold 62,116 70,126 Research and development 58,174 73,933 Selling, general and administrative 146,994 169,789 Amortization of acquired intangible assets 14 8,996 Total Expenses 267,298 322,844 Operating Income 162,688 54,631 Other Income, net: Interest income 11,400 9,749 Interest expense (4,648) (6,054) Other income (expense), net 449 (10) Total Other Income, net 7,201 3,685 Income Before Income Taxes 169,889 58,316 Income Tax Provision (Benefit) 24,152 (102,236) Net Income From Continuing Operations 145,737 160,552 Income (Loss) From Discontinued Operations — Net of Tax 766 (47,773) Net Income — GAAP $ 146,503 $ 112,779 GAAP Earnings (Loss) Per Ordinary Share - Basic: From continuing operations $ 0.90 $ 0.96 From discontinued operations $ 0.00 $ (0.29) From net income $ 0.90 $ 0.68 GAAP Earnings (Loss) Per Ordinary Share - Diluted: From continuing operations $ 0.88 $ 0.94 From discontinued operations $ 0.00 $ (0.28) From net income $ 0.88 $ 0.66 Weighted Average Number of Ordinary Shares Outstanding: Basic — GAAP and Non-GAAP 161,956 166,898 Diluted — GAAP and Non-GAAP 166,554 170,138 Condensed Consolidated Statements of Operations - GAAP (Continued) Three Months Ended Three Months Ended (In thousands, except per share data) December 31, 2024 December 31, 2023 An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows: Net Income from Continuing Operations $ 145,737 $ 160,552 Adjustments: Depreciation expense 6,833 9,225 Amortization expense 14 8,996 Interest income (11,400) (9,749) Interest expense 4,648 6,054 Income tax provision (benefit) 24,152 (102,236) EBITDA from Continuing Operations 169,984 72,842 EBITDA from Discontinued Operations 1,120 (40,537) EBITDA $ 171,104 $ 32,305 An itemized reconciliation between net income from continuing operations on a GAAP basis and non-GAAP net income is as follows: Net Income from Continuing Operations $ 145,737 $ 160,552 Adjustments: Share-based compensation expense 20,747 22,776 Depreciation expense 6,833 9,225 Amortization expense 14 8,996 Loss on debt extinguishment 719 — Income tax effect related to reconciling items (629) 22,011 Separation expense — 19,084 Non-cash net interest expense — 115 Deferred tax valuation release — (160,953) Non-GAAP Net Income from Continuing Operations 173,421 81,806 Non-GAAP Net Income (Loss) from Discontinued Operations 766 (44,383) Non-GAAP Net Income $ 174,187 $ 37,423 Non-GAAP diluted earnings per ordinary share from continuing operations $ 1.04 $ 0.48 Non-GAAP diluted loss per ordinary share from discontinued operations $ 0.00 $ (0.26) Non-GAAP diluted earnings per ordinary share from net income $ 1.05 $ 0.22 Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Statements of Operations - GAAP Year Ended Year Ended (In thousands, except per share data) December 31, 2024 December 31, 2023 Revenues: Product sales, net $ 1,083,534 $ 919,998 Manufacturing and royalty revenues 474,095 743,388 Research and development revenue 3 19 Total Revenues 1,557,632 1,663,405 Expenses: Cost of goods manufactured and sold 245,331 253,037 Research and development 245,326 270,806 Selling, general and administrative 645,238 689,751 Amortization of acquired intangible assets 1,101 35,689 Total Expenses 1,136,996 1,249,283 Operating Income 420,636 414,122 Other Income, net: Interest income 42,450 30,854 Interest expense (22,578) (23,032) Other income (expense), net 3,242 (425) Total Other Income, net 23,114 7,397 Income Before Income Taxes 443,750 421,519 Income Tax Provision (Benefit) 71,612 (97,638) Net Income From Continuing Operations 372,138 519,157 Loss From Discontinued Operations — Net of Tax (5,068) (163,400) Net Income — GAAP $ 367,070 $ 355,757 GAAP Earnings (Loss) Per Ordinary Share - Basic: From continuing operations $ 2.25 $ 3.12 From discontinued operations $ (0.03) $ (0.98) From net income $ 2.22 $ 2.14 GAAP Earnings (Loss) Per Ordinary Share - Diluted: From continuing operations $ 2.20 $ 3.06 From discontinued operations $ (0.03) $ (0.96) From net income $ 2.17 $ 2.10 Weighted Average Number of Ordinary Shares Outstanding: Basic — GAAP and Non-GAAP 165,392 166,223 Diluted — GAAP and Non-GAAP 169,198 169,730 Condensed Consolidated Statements of Operations - GAAP (Continued) Year Ended Year Ended (In thousands, except per share data) December 31, 2024 December 31, 2023 An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows: Net Income from Continuing Operations $ 372,138 $ 519,157 Adjustments: Depreciation expense 27,432 36,921 Amortization expense 1,101 35,689 Interest income (42,450) (30,854) Interest expense 22,578 23,032 Income tax provision (benefit) 71,612 (97,638) EBITDA from Continuing Operations 452,411 486,307 EBITDA from Discontinued Operations (5,790) (162,484) EBITDA $ 446,621 $ 323,823 An itemized reconciliation between net income from continuing operations on a GAAP basis and non-GAAP net income is as follows: Net Income from Continuing Operations $ 372,138 $ 519,157 Adjustments: Share-based compensation expense 96,636 92,719 Depreciation expense 27,432 36,921 Amortization expense 1,101 35,689 Separation expense 1,446 38,364 Loss on debt extinguishment 719 — Gain on sale of Athlone manufacturing facility (1,462) — Income tax effect related to reconciling items (3,945) 25,343 Deferred tax valuation release — (160,953) Restructuring expense — 5,938 Final award in the Janssen arbitration (2022 back royalties and interest) — (197,092) Non-cash net interest expense 342 461 Non-GAAP Net Income from Continuing Operations 494,407 396,547 Non-GAAP Net Loss from Discontinued Operations (5,068) (152,894) Non-GAAP Net Income $ 489,339 $ 243,653 Non-GAAP diluted earnings per ordinary share from continuing operations $ 2.92 $ 2.34 Non-GAAP diluted loss per ordinary share from discontinued operations $ (0.03) $ (0.90) Non-GAAP diluted earnings per ordinary share from net income $ 2.89 $ 1.44 Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Balance Sheets December 31, December 31, (In thousands) 2024 2023 Cash, cash equivalents and total investments $ 824,816 $ 813,378 Receivables 389,733 332,477 Inventory 182,887 186,406 Contract assets 4,990 706 Prepaid expenses and other current assets 86,077 98,166 Property, plant and equipment, net 227,564 226,943 Intangible assets, net and goodwill 83,917 85,018 Assets held for sale — 94,260 Deferred tax assets 154,835 195,888 Other assets 100,748 102,981 Total Assets $ 2,055,567 $ 2,136,223 Long-term debt — current portion $ — $ 3,000 Other current liabilities 465,199 512,678 Long-term debt — 287,730 Liabilities from discontinued operations — 4,542 Other long-term liabilities 125,391 125,587 Total shareholders' equity 1,464,977 1,202,686 Total Liabilities and Shareholders' Equity $ 2,055,567 $ 2,136,223 Ordinary shares outstanding (in thousands) 162,177 166,980 This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Annual Report on Form 10-K for the year ended December 31, 2024, which the company intends to file in February 2025. Alkermes plc and Subsidiaries Amounts Included in Discontinued Operations (In thousands) Three MonthsEndedMarch 31,2024 Three MonthsEndedJune 30,2024 Three MonthsEndedSeptember 30,2024 Three MonthsEndedDecember 31,2024 YearEndedDecember 31,2024 Cost of goods manufactured and sold $ — $ — $ — $ — $ - Research and development 2,516 3,913 481 (1,120) 5,790 Selling, general and administrative — — — — - Income tax (benefit) provision (396) (613) (67) 354 (722) (Income) Loss from discontinued operations, net of tax $ 2,120 $ 3,300 $ 414 $ (766) $ 5,068 (In thousands) Three MonthsEndedMarch 31,2023 Three MonthsEndedJune 30,2023 Three MonthsEndedSeptember 30,2023 Three MonthsEndedDecember 31,2023 YearEndedDecember 31,2023 Cost of goods manufactured and sold $ 11 $ 11 $ 11 $ 6 $ 39 Research and development 29,867 32,563 32,262 21,485 116,177 Selling, general and administrative 6,644 9,502 13,073 19,368 48,587 Income tax (benefit) provision (6,727) (40) (1,550) 6,914 (1,403) Loss from discontinued operations, net of tax $ 29,795 $ 42,036 $ 43,796 $ 47,773 $ 163,400 Alkermes plc and Subsidiaries Revenues for Calendar Year 2024 and 2023 (In thousands) Three MonthsEndedMarch 31,2024 Three MonthsEndedJune 30,2024 Three MonthsEndedSeptember 30,2024 Three MonthsEndedDecember 31,2024 YearEndedDecember 31,2024 Revenues: VIVITROL $ 97,659 $ 111,873 $ 113,650 $ 134,133 $ 457,315 ARISTADA 78,870 86,049 84,652 96,616 346,187 LYBALVI 57,007 71,351 74,697 76,977 280,032 Total Proprietary Sales 233,536 269,273 272,999 307,726 1,083,534 PARTNERED LONG-ACTING ANTIPSYCHOTICS (1) 65,391 82,297 60,876 51,267 259,831 VUMERITY 31,254 35,234 32,574 34,985 134,047 Key Commercial Product Revenues 330,181 386,804 366,449 393,978 1,477,412 Legacy Product Revenues 20,188 12,327 11,694 36,008 80,217 Research and Development Revenues 3 — — — 3 Total Revenues $ 350,372 $ 399,131 $ 378,143 $ 429,986 $ 1,557,632 (In thousands) Three MonthsEndedMarch 31,2023 Three MonthsEndedJune 30,2023 Three MonthsEndedSeptember 30,2023 Three MonthsEndedDecember 31,2023 YearEndedDecember 31,2023 Revenues: VIVITROL $ 96,659 $ 102,070 $ 99,305 $ 102,385 $ 400,419 ARISTADA 80,077 82,410 81,834 83,369 327,690 LYBALVI 37,991 46,997 50,683 56,218 191,889 Total Proprietary Sales 214,727 231,477 231,822 241,972 919,998 PARTNERED LONG-ACTING ANTIPSYCHOTICS (1) 24,543 326,380 90,993 81,461 523,377 VUMERITY 28,874 32,295 34,561 33,596 129,326 Key Commercial Product Revenues 268,144 590,152 357,376 357,029 1,572,701 Legacy Product Revenues 19,445 27,238 23,559 20,443 90,685 Research and Development Revenues 6 7 3 3 19 Total Revenues $ 287,595 $ 617,397 $ 380,938 $ 377,475 $ 1,663,405 (1) - Includes RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI. Alkermes plc and Subsidiaries 2025 Guidance — GAAP to EBITDA and Adjusted EBITDA An itemized reconciliation between projected net income on a GAAP basis, EBITDA and Adjusted EBITDA is as follows: (In millions) Amount Projected Net Income — GAAP $ 190.0 Adjustments: Interest income (30.0) Depreciation and amortization expense 30.0 Provision for income taxes 40.0 Projected EBITDA $ 230.0 Share-based compensation expense 95.0 Projected Adjusted EBITDA $ 325.0 Projected Net Income on a GAAP basis and Projected EBITDA and Projected Adjusted EBITDA reflect mid-points within ranges of estimated guidance. Alkermes Contacts:For Investors: Sandy Coombs +1 781 609 6377For Media: Katie Joyce +1 781 249 8927 SOURCE Alkermes plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News